[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,482,008
  • Shares Outstanding, K 93,798
  • Annual Sales, $ 0 K
  • Annual Income, $ -313,940 K
  • EBIT $ -298 M
  • EBITDA $ -297 M
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.75

Options Overview Details

View History
  • Implied Volatility 113.52% (+17.76%)
  • Historical Volatility 266.17%
  • IV Percentile 11%
  • IV Rank 7.16%
  • IV High 667.58% on 10/15/25
  • IV Low 70.80% on 08/19/26
  • Expected Move (DTE 2) 0.82 (5.31%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 276
  • Volume Avg (30-Day) 18,279
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 106,235
  • Open Int (30-Day) 226,406
  • Expected Range 14.56 to 16.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.75
  • Number of Estimates 4
  • High Estimate $-0.60
  • Low Estimate $-1.02
  • Prior Year $-0.90
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.76 +217.33%
on 07/29/26
15.89 -4.85%
on 08/25/26
+5.42 (+55.88%)
since 07/24/26
3-Month
4.47 +238.26%
on 05/27/26
15.89 -4.85%
on 08/25/26
+10.52 (+228.70%)
since 05/26/26
52-Week
1.50 +908.00%
on 04/13/26
15.89 -4.85%
on 08/25/26
+9.44 (+166.20%)
since 08/26/25

Most Recent Stories

More News
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky

Investors allege Replimune Group, Inc. supported its RP1 biologics license resubmission with data from an early unplanned analysis covering only 40 patients — roughly 10% of planned enrollment...

REPL : 15.35 (-2.85%)
Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , Aug. 25, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz  announces that investors with losses related to Replimune Group, Inc. (REPL) have opportunity to lead the securities...

REPL : 15.35 (-2.85%)
Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , Aug. 25, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP  announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

REPL : 15.35 (-2.85%)
Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action

SAN DIEGO , Aug. 21, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP  reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise...

REPL : 15.35 (-2.85%)
REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

Disclosure Under Scrutiny: Replimune's SEC filings warned generally that RP1 might not win approval, yet allegedly omitted that the FDA had already told the Company its study design concerns were...

REPL : 15.35 (-2.85%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

NEW YORK , Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors...

REPL : 15.35 (-2.85%)
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 15.35 (-2.85%)
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

Disclosure Under Scrutiny: Replimune's SEC filings warned generally that RP1 might not win approval, yet allegedly omitted that the FDA had already told the Company its study design concerns were...

REPL : 15.35 (-2.85%)
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

NEW YORK , Aug. 18, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Replimune Group, Inc. (NASDAQ: REPL).

REPL : 15.35 (-2.85%)
Did You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPL

San Diego, California--(Newsfile Corp. - August 17, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased...

REPL : 15.35 (-2.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United...

See More

Key Turning Points

3rd Resistance Point 17.56
2nd Resistance Point 16.73
1st Resistance Point 16.26
Last Price 15.35
1st Support Level 14.96
2nd Support Level 14.13
3rd Support Level 13.66

See More

52-Week High 15.89
Last Price 15.35
Fibonacci 61.8% 10.39
Fibonacci 50% 8.69
Fibonacci 38.2% 7.00
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.